JP2023525757A - Akt3モジュレーター - Google Patents

Akt3モジュレーター Download PDF

Info

Publication number
JP2023525757A
JP2023525757A JP2022567882A JP2022567882A JP2023525757A JP 2023525757 A JP2023525757 A JP 2023525757A JP 2022567882 A JP2022567882 A JP 2022567882A JP 2022567882 A JP2022567882 A JP 2022567882A JP 2023525757 A JP2023525757 A JP 2023525757A
Authority
JP
Japan
Prior art keywords
compound
disease
independently
alkyl
structural part
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022567882A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023525757A5 (cg-RX-API-DMAC10.html
Inventor
クレイフ,サミル
ムクルティチャン,ミカエル
マッコス,マルコム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgiamune Inc
Original Assignee
Georgiamune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgiamune Inc filed Critical Georgiamune Inc
Publication of JP2023525757A publication Critical patent/JP2023525757A/ja
Publication of JP2023525757A5 publication Critical patent/JP2023525757A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Amplifiers (AREA)
  • Burglar Alarm Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2022567882A 2020-05-08 2021-05-07 Akt3モジュレーター Pending JP2023525757A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063022111P 2020-05-08 2020-05-08
US63/022,111 2020-05-08
US202063120984P 2020-12-03 2020-12-03
US63/120,984 2020-12-03
PCT/US2021/031381 WO2021226517A1 (en) 2020-05-08 2021-05-07 Akt3 modulators

Publications (2)

Publication Number Publication Date
JP2023525757A true JP2023525757A (ja) 2023-06-19
JP2023525757A5 JP2023525757A5 (cg-RX-API-DMAC10.html) 2024-05-16

Family

ID=78468495

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022567882A Pending JP2023525757A (ja) 2020-05-08 2021-05-07 Akt3モジュレーター

Country Status (12)

Country Link
US (1) US20230295114A1 (cg-RX-API-DMAC10.html)
EP (1) EP4146666A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023525757A (cg-RX-API-DMAC10.html)
KR (1) KR20230022456A (cg-RX-API-DMAC10.html)
CN (1) CN115996939A (cg-RX-API-DMAC10.html)
AU (1) AU2021268210A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022022342A2 (cg-RX-API-DMAC10.html)
CA (1) CA3182673A1 (cg-RX-API-DMAC10.html)
IL (1) IL297598A (cg-RX-API-DMAC10.html)
MX (1) MX2022014020A (cg-RX-API-DMAC10.html)
PH (1) PH12022553031A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021226517A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023525756A (ja) * 2020-05-08 2023-06-19 ジョージアミューン・インコーポレイテッド Akt3モジュレーター

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021212111A1 (en) * 2020-04-17 2021-10-21 Augusta University Research Institute, Inc. Compositions and methods for treating leukemia
IL312439A (en) * 2021-11-05 2024-06-01 Georgiamune Inc Akt3 modulators

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002516327A (ja) * 1998-05-26 2002-06-04 ワーナー−ランバート・カンパニー 細胞増殖の阻害剤としての二環式ピリミジンおよび二環式3,4−ジヒドロピリミジン
WO2007076474A1 (en) * 2005-12-23 2007-07-05 Kalypsys, Inc. Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases
JP2007530453A (ja) * 2004-03-19 2007-11-01 ザ ペン ステート リサーチ ファウンデーション 黒色腫を治療するためのコンビナトリアル法および組成物
JP2008538749A (ja) * 2005-04-15 2008-11-06 セレプ・ソシエテ・アノニム Npy拮抗物質、調製および使用
JP2010506856A (ja) * 2006-10-12 2010-03-04 スーパージェン, インコーポレイテッド Dnaメチル化を調整するためのキノリン誘導体
JP2011500591A (ja) * 2007-10-12 2011-01-06 スーパージェン, インコーポレイテッド Dnaメチル化を調整するためのキノリン誘導体
CN102659628A (zh) * 2012-04-26 2012-09-12 四川大学 含芳酰胺的邻苯二甲腈单体及其合成方法和用其固化制备的聚邻苯二甲腈树脂
CN102775389A (zh) * 2012-04-05 2012-11-14 华侨大学 N-取代-4-(7-氯喹啉-4-氨基)-苯甲酰胺衍生物的制备方法和应用
US20140004620A1 (en) * 2011-03-07 2014-01-02 Cosimo Prete Visualization kit comprising a fluorescent agent and a cyanoacrylate, and method of cofumigation of a fluorescent agent and a cyanoacrylate
WO2014015056A2 (en) * 2012-07-17 2014-01-23 Washington University Anti-mucus drugs and uses therefor
WO2017039318A1 (en) * 2015-09-01 2017-03-09 Kainos Medicine, Inc. Benzimidazole derivatives for dna methylation inhibitors
CN106749071A (zh) * 2017-01-10 2017-05-31 江西师范大学 一种芳香类1,2,4,5‑四嗪化合物的制备方法
US20170202956A1 (en) * 2016-01-15 2017-07-20 Augusta University Research Institute, Inc. Methods and Compositions for Inhibiting Akt3
US20170202829A1 (en) * 2016-01-15 2017-07-20 Augusta University Research Institute, Inc. Specific Akt3 Inhibitor and Uses Thereof Cross-Reference to Related Applications
WO2019051063A1 (en) * 2017-09-07 2019-03-14 Augusta University Research Institute, Inc. Specific akt3 activator and uses thereof
WO2019079596A1 (en) * 2017-10-18 2019-04-25 Epizyme, Inc. METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES
JP2023525758A (ja) * 2020-05-08 2023-06-19 ジョージアミューン・インコーポレイテッド Akt3モジュレーターおよびその使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5746015B2 (ja) * 2008-04-16 2015-07-08 マックス プランク ゲゼルシャフト ツゥアー フェデルゥン デル ヴィッセンシャフテン エー フォー Axlキナーゼ阻害剤としてのキノリン誘導体
BR112012011328A2 (pt) * 2009-10-23 2016-11-22 Lilly Co Eli inibidores de akt
US10519113B2 (en) * 2016-08-17 2019-12-31 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds, compositions, and methods of treating cancer
CN114181199B (zh) * 2020-09-15 2023-09-26 成都赜灵生物医药科技有限公司 2,4-二取代嘧啶衍生物及其制备方法和用途

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002516327A (ja) * 1998-05-26 2002-06-04 ワーナー−ランバート・カンパニー 細胞増殖の阻害剤としての二環式ピリミジンおよび二環式3,4−ジヒドロピリミジン
JP2007530453A (ja) * 2004-03-19 2007-11-01 ザ ペン ステート リサーチ ファウンデーション 黒色腫を治療するためのコンビナトリアル法および組成物
JP2008538749A (ja) * 2005-04-15 2008-11-06 セレプ・ソシエテ・アノニム Npy拮抗物質、調製および使用
WO2007076474A1 (en) * 2005-12-23 2007-07-05 Kalypsys, Inc. Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases
JP2010506856A (ja) * 2006-10-12 2010-03-04 スーパージェン, インコーポレイテッド Dnaメチル化を調整するためのキノリン誘導体
JP2011500591A (ja) * 2007-10-12 2011-01-06 スーパージェン, インコーポレイテッド Dnaメチル化を調整するためのキノリン誘導体
US20140004620A1 (en) * 2011-03-07 2014-01-02 Cosimo Prete Visualization kit comprising a fluorescent agent and a cyanoacrylate, and method of cofumigation of a fluorescent agent and a cyanoacrylate
CN102775389A (zh) * 2012-04-05 2012-11-14 华侨大学 N-取代-4-(7-氯喹啉-4-氨基)-苯甲酰胺衍生物的制备方法和应用
CN102659628A (zh) * 2012-04-26 2012-09-12 四川大学 含芳酰胺的邻苯二甲腈单体及其合成方法和用其固化制备的聚邻苯二甲腈树脂
WO2014015056A2 (en) * 2012-07-17 2014-01-23 Washington University Anti-mucus drugs and uses therefor
WO2017039318A1 (en) * 2015-09-01 2017-03-09 Kainos Medicine, Inc. Benzimidazole derivatives for dna methylation inhibitors
US20170202956A1 (en) * 2016-01-15 2017-07-20 Augusta University Research Institute, Inc. Methods and Compositions for Inhibiting Akt3
US20170202829A1 (en) * 2016-01-15 2017-07-20 Augusta University Research Institute, Inc. Specific Akt3 Inhibitor and Uses Thereof Cross-Reference to Related Applications
CN106749071A (zh) * 2017-01-10 2017-05-31 江西师范大学 一种芳香类1,2,4,5‑四嗪化合物的制备方法
WO2019051063A1 (en) * 2017-09-07 2019-03-14 Augusta University Research Institute, Inc. Specific akt3 activator and uses thereof
WO2019079596A1 (en) * 2017-10-18 2019-04-25 Epizyme, Inc. METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES
JP2023525758A (ja) * 2020-05-08 2023-06-19 ジョージアミューン・インコーポレイテッド Akt3モジュレーターおよびその使用方法

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
GAMAGE, S. A. ET AL.: "Structure-activity relationships for 4-anilinoquinoline derivatives as inhibitors of the DNA methylt", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 21, no. 11, JPN6025018000, 2013, pages 3147 - 3153, ISSN: 0005587402 *
LIANG, X. ET AL.: "Discovery of 2-((3-Acrylamido-4-methylphenyl)amino)-N-(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)", JOURNAL OR MEDICINAL CHEMISTRY, vol. 60, no. 5, JPN6025018005, 2017, pages 1793 - 1816, ISSN: 0005587409 *
LIANG, X. ET AL.: "Discovery of N-(4-(6-acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMF", JOURNAL OF MEDICINAL CHEMISTRY, vol. 62, no. 2, JPN6025018003, 2019, pages 875 - 892, ISSN: 0005587405 *
PUBCHEM, JPN6025018004, 31 May 2019 (2019-05-31), pages 1 - 5, ISSN: 0005587407 *
REGISTRY(STN)[ONLINE], JPN7025001917, pages 1 - 4, ISSN: 0005587406 *
SHAO, W. ET AL.: "The synthesis and anti-tumor activity research of a novel quinazoline derivatives", HUAXI YAOXUE ZAZHI, vol. 28, no. 3, JPN6025018006, 2013, pages 232 - 234, ISSN: 0005587408 *
VALENTE, S. ET AL.: "Selective Non-nucleoside Inhibitors of Human DNA Methyltransferases Active in Cancer Including in Ca", JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, no. 3, JPN6025018001, 2014, pages 701 - 713, ISSN: 0005587403 *
ZHANG, JIU-YUN ET AL.: "Synthesis of 4-substituted-7-chloroquinoline derivatives and preliminary evaluation of their antitum", ZHONGGUO XINYAO ZAZHI, vol. 23, no. 5, JPN6025018002, 2014, pages 585 - 590, ISSN: 0005587404 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023525756A (ja) * 2020-05-08 2023-06-19 ジョージアミューン・インコーポレイテッド Akt3モジュレーター
JP7757312B2 (ja) 2020-05-08 2025-10-21 ジョージアミューン・インコーポレイテッド Akt3モジュレーター

Also Published As

Publication number Publication date
EP4146666A4 (en) 2024-10-16
CA3182673A1 (en) 2021-11-11
PH12022553031A1 (en) 2024-05-13
US20230295114A1 (en) 2023-09-21
EP4146666A1 (en) 2023-03-15
AU2021268210A1 (en) 2022-12-15
MX2022014020A (es) 2023-02-16
CN115996939A (zh) 2023-04-21
KR20230022456A (ko) 2023-02-15
BR112022022342A2 (pt) 2023-01-03
WO2021226517A1 (en) 2021-11-11
IL297598A (en) 2022-12-01

Similar Documents

Publication Publication Date Title
JP2026004302A (ja) Akt3モジュレーター
KR20230022456A (ko) Akt3 조절제
US20250002511A1 (en) Akt3 modulators
JP2026027231A (ja) Akt3モジュレーター
JP2024540107A (ja) Akt3モジュレーター
JP2023524600A (ja) Akt3モジュレーター
JP2024541975A (ja) Akt3モジュレーター
JP2024541994A (ja) Akt3モジュレーター
HK40113514A (en) Akt3 modulators
HK40084745A (en) Akt3 modulators
HK40084847A (en) Akt3 modulators
HK40115337A (en) Akt3 modulators
HK40084844A (en) Akt3 modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240502

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250806

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260526

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260804